Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?

This article was originally published in The Pink Sheet Daily

Executive Summary

New England Journal of Medicine editorial says cost-effectiveness data and head-to-head studies on new oral anticoagulants are needed to move prescribing away from warfarin for atrial fibrillation patients.
Advertisement

Related Content

Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
With Strong Q3 Financials, Pfizer Says It's Ready For Generic Competition To Lipitor
Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval
Xarelto's Comparative Efficacy To Warfarin, Pradaxa Will Be Focus At FDA Panel Review
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Bristol/Pfizer's Apixaban: Third To Market But Best-In-Class?
Bristol/Pfizer's Apixaban: Third To Market But Best-In-Class?
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option

Topics

Advertisement
UsernamePublicRestriction

Register

PS072701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel